Science, policy, therapy, harm reduction, and culture — decoded twice a week for the curious, the informed, and everyone in between.
Your first issue is on its way. Welcome to The Insightful Trip.
What You Get
Clinical trials, neuroscience breakthroughs, and the latest studies on psilocybin, MDMA, LSD, ketamine, and emerging compounds. Translated for humans.
State-by-state tracking. Federal movements. International reforms. Who's legalizing what, and what it means for access.
Psychedelic-assisted therapy for depression, PTSD, addiction, and end-of-life anxiety. Practitioner guides. Integration frameworks.
Substance guides, dosing information, drug interactions, set and setting, and evidence-based safety practices. No judgment.
Indigenous traditions, the counterculture era, modern psychedelic art, music, and the people shaping this movement.
Market trends, company news, investment flows, and the commercial side of the psychedelic renaissance.
Why Now
2026 is shaping up to be the year of psychedelic drug approvals. Billions in investment. Dozens of state bills. Mainstream coverage from the NYT to 60 Minutes.
The conversation has shifted from "if" to "how fast." There's never been more to know, and no single place that covers all of it. Until now.
Recent Coverage
Psychedelics are reshaping mental health, culture, and consciousness. Don't miss a thing.
Your first issue is on its way. Welcome to The Insightful Trip.